1. To evaluate the potential contribution of thromboxane A
2 (TXA
2) and prostaglandin I
2 (PGI
2) to the development of chronic glomerulonephritis, urinary excretion of TXB
2, 2, 3-dinor-TXB
2 and 6-keto-PGF
1α was measured by radio-immunoassay in patients with chronic glomerulonephritis. In patients with nephrotic syndrome, urinary excretion of TXB
2 and 2, 3-dinor-TXB
2 was highly increased, whereas that of 6-keto-PGF
1α remained normal In patients with non-nephrotic chronic glomerulonephritis, urinary excretion of TXB
2 was significantly increased, whereas that of 2, 3-dinor-TXB
2 and 6-keto-PGF
1α remained normal. In patients with chronic renal failure, urinary excretion of TXB
2, 2, 3-dinor-TXB
2 and 6-keto-PGF
1α was markedly decreased. 2. To determine if a selective TXA
2 synthetase inhibitor is an effective drug for chronic glomerulonephritis, 10 patients including 7 with nephrotic syndrome were treated only with OKY-046 for 8 weeks, Urinary excretion of protein, TXB
2, 2, 3-dinor-TXB
2 and fibrinogen/fibrin degradation products (FDP) decreased significantly with OKY-046. Urinary excretion of 6-keto-PGF
1α increased significantly, Creatinine clearance, however, did not change significantly. Serum level of albumin increased significantly, and that of total cholesterol and plasma level of fibrinogen decreased, Platelet aggregation induced by 2μg/ml collagen was significantly inhibited with OKY-046, One patient with minimal change nephrotic syndrome showed complete remission only with OKY-046. 3. These results demonstrate that TXA
2 plays an important role as an exaggerating factor in the development of chronic glomerulonephritis particularly that accomparying nephrotic syndrome, and that the selective TXA
2 synthetase inhibitor is an effective drug for the treatment of chronic glomerulonephritis especially with nephrotic syndrome.
View full abstract